Nitric Oxide Innovations (NOi) Drug Company Founder and CEO Nathan Bryan, Ph.D. Proudly Announces David Perlmutter, M.D., Board-Certified Neurologist and Six-Time New York Times Bestselling Author, Has Joined (NOi) to Lead Alzheimer’s Neurodegenerative Dr


BEVERLY HILLS, CA – (NewMediaWire) – June 27, 2023 – Announced today:  Nitric Oxide Innovations (NOi) drug company founder and CEO, Nathan S. Bryan Ph.D proudly announces that world renowned  board certified neurologist, six-time New York Times bestselling Author David Perlmutter, M.D. has joined (NOi) to lead the N101 Alzheimer’s and neurodegenerative drug program. Dr. Bryan, (NOi) and Pneuma Nitric Oxide, LLC are represented by Alan Morell and Creative Management Partners (CMP), Beverly Hills, CA.

Said Dr. Nathan Bryan Ph D., “I am extremely proud and honored to announce that Dr. David Perlmutter, board certified neurologist and one of the first to recognize Alzheimer’s’ disease as a metabolic disease, as our Director of Neuroscience Research.  As we enter into clinical trials on Alzheimer’s disease with our nitric oxide drug, there is no one more qualified to guide our development program on neurodegenerative disease.  We realize nitric oxide is a game changer in therapeutics.  It improves circulation, reduces inflammation, oxidative stress and immune dysfunction but also improves insulin signaling and cellular metabolism, the underlying causes of neurodegenerative disease, including Alzheimer’s disease.  With Dr. Permutter’s guidance, we hope to expedite our Alzheimer’s drug study and finally get a safe and effective treatment approved for this horrible degenerative disease.  Everything we know about the cause of Alzheimer’s disease appears to be corrected by nitric oxide.” 

Said David Perlmutter M.D: “I’m absolutely thrilled to be joining Nitric Oxide Innovations, a vanguard in this exciting science, and directing our collective energies towards understanding the pivotal connection between metabolic dysfunction and Alzheimer’s disease. Recognizing nitric oxide’s important role in brain metabolism offers us an exciting avenue to create interventions targeting disease progression. We will unravel what is clearly a complex issue, and in doing so, offer hope and new solutions for those affected by Alzheimer’s disease.”


David Perlmutter, M.D. is a Board-Certified Neurologist and six-time New York Times bestselling author. He serves on the Board of Directors and is a Fellow of the American College of Nutrition.

Dr. Perlmutter received his M.D. degree from the University of Miami School of Medicine where he was awarded the Leonard G. Rowntree Research Award. He serves as a member of the Editorial Board for the Journal of Alzheimer’s Disease and has published extensively in peer-reviewed scientific journals including Archives of Neurology, Neurosurgery, and The Journal of Applied Nutrition. In addition, he is a frequent lecturer at symposia sponsored by institutions such as the World Bank and IMF, Columbia University, Scripps Institute, New York University, and Harvard University, and serves as an Associate Professor at the University of Miami Miller School of Medicine.

His books have been published in 32 languages and include the #1 New York Times bestseller Grain Brain, The Surprising Truth About Wheat, Carbs and Sugar, with over 1 million copies in print. Other New York Times bestsellers include Brain Maker, The Grain Brain Cookbook, The Grain Brain Whole Life Plan, and Brain Wash, co-written with Austin Perlmutter, M.D. He is the editor of The Microbiome and the Brain authored by top experts in the field and published in December 2019 by CRC Press. His latest book, Drop Acid, focuses on the pivotal role of uric acid in metabolic diseases, and was published in February 2022.

Dr. Perlmutter is also the recipient of numerous awards, including: the Linus Pauling Award for his innovative approaches to neurological disorders; the National Nutritional Foods Association Clinician of the Year Award, the Humanitarian of the Year Award from the American College of Nutrition, and most recently the 2019 Global Leadership Award from the Integrative Healthcare Symposium.


Our Mission:

Nitric Oxide innovations (NOi) was established to commercialize clinically and scientifically proven Nitric Oxide (NO) based technologies for a wide range of human disease and conditions. Our mission is to be the industry leader and innovator in nitric oxide-based technologies in order to bring to market safe and effective therapeutic solutions where NO may be involved.

Our Philosophy & Vision:

Honor, integrity, transparency and trusting relationships will guide our business decisions. Our philosophy is that if we stay true to the science of NO and harness the potential it has to change the landscape of human disease and health care, we will change the world and leave a lasting legacy on mankind.

Our vision for Nitric Oxide Innovations is to be an innovative nitric oxide focused bio-technology company providing safe and effective therapeutics for a number of human diseases and applications.

Dr. Bryan earned his undergraduate Bachelor of Science degree in Biochemistry from the University of Texas at Austin and his doctoral degree from Louisiana State University Health Sciences Center  in Shreveport, where he was the recipient of the Dean’s Award for Excellence in  Research.  He pursued his post-doctoral training as a Kirschstein Fellow at Boston University School of Medicine in the Whitaker Cardiovascular Institute.  After a two year post-doctoral fellowship, in 2006 Dr. Bryan was recruited to join faculty at the University of Texas Health Science Center at Houston by Ferid Murad, M.D., Ph.D., 1998 Nobel Laureate in Medicine or Physiology.  Dr. Bryan has been involved in nitric oxide research for the past 20 years and has 

made many seminal discoveries in the field.  His many seminal discoveries have resulted in dozens of issued US and International patents and the product technology resulting from his discoveries and inventions has improved patient care worldwide.  Most recently, Dr. Bryan serves as Founder and CEO of Nitric Oxide Innovations (NOi), a privately-held, clinical-stage biopharmaceutical company that is actively engaged in the discovery and development of nitric oxide based therapies for ischemic heart disease, ischemic, non-obstructive coronary disease, Alzheimer’s disease and topical wound care for pressure ulcers.  Dr. Bryan is an international leader in molecular medicine and nitric oxide biochemistry.  

For further information go to: 



Dr. Nathan S. Bryan

Nitric Oxide Innovations Drug Company Founder and CEO

Contact Information:                                                                                                                   


Creative Management Partners LLC (CMP)

Beverly Hills Gardens Building 

9440 Santa Monica Blvd. Suite 301, 

Beverly Hills, Ca. 90210 / 508-292-7900


Source link

Show More

Related Articles

Trending Tickers

Back to top button